IL6 and cancer: Overall, our study re-emphasizes the heterogeneous spectrum of MDSC subsets identified in cancer patients, and suggests that the IL-6/IL-8-arginase I axis is a potential therapeutic target for the ablation of MDSC-mediated immunosuppression in GC patients.